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Abstract 
Inflammation is a well-known driver of carcinogenesis and cancer progression, often attributed to the 
tumor microenvironment. However, tumor cells themselves are capable of secreting a variety of 
inflammatory molecules, leading to the activation of specific signaling pathways that promote tumor 
progression. The NF-κB signaling pathway is one of the most important connections between 
inflammation and tumorigenesis. NF-κB is a superfamily of transcription factors that plays an important 
role in several types of hematological and solid tumors, including breast cancer. However, the role of the 
NF-κB pathway in the survival of breast cancer patients is poorly studied. In this study, we analyzed and 
related the expression of both canonical and alternative NF-κB pathways and selected target genes with 
the relapse-free and overall survival of breast cancer patients. We used the public database Kaplan-Meier 
plotter (KMplot) which includes gene expression data and survival information of 3951 breast cancer 
patients. We found that the expression of IKKα was associated with poor relapse-free survival in patients 
with ER-positive tumors. Moreover, the expression of IL-8 and MMP-1 was associated with poor 
relapse-free and overall survival. In contrast, expression of IKKβ, p50, and p65 from the canonical 
pathway, and NIK and RELB from the alternative pathway correlated with better relapse-free survival also 
when the patients were classified by their hormonal and nodal status. Our study suggests that the 
expression of genes of the canonical and alternative NF-κB pathways is ultimately critical for tumor 
persistence. Understanding the communication between both pathways would help to find better 
therapeutic and prophylactic targets to prevent breast cancer progression and relapse. 
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Introduction 
In recent years, the clinical problem of breast 
cancer diagnosis and treatment gained increasing 
public attention. Breast cancer is the most common 
cause of cancer mortality in young productive 
women, especially in developing countries [1]. The 
current problem with breast cancer is that it is a 
highly heterogeneous disease both inter- and 
intra-tumoral and it is classified into different 
subtypes with variable clinical outcomes [2, 3]. The 
markers and clinical parameters known to date 
(tumor size, expression of estrogen and progesterone 
receptors, and HER-2/neu, histological or nuclear 
grade) are not applicable in all clinical stages and 
between the patients, and limit their utility to decide 
the most appropriate chemotherapeutic treatment 
since they have shown a weak association with the 
clinical response of patients [4]. The involvement of 
axillary lymph nodes has been shown to be the most 
important predictor of disease-free survival and 
overall survival in breast cancer [5, 6]. Approximately 
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30% of lymph node-negative patients have a relapse 
within 10 years, compared with around 70% of 
patients with axillary nodal positive involvement [7, 
8]. We need to understand more about this disease in 
order to find specific biomarkers and potential drug 
targets that help to change the prognostic of the 
patient.  
In addition, breast cancer cells are surrounded 
by a microenvironment, the tumor microenvironment 
(TME), composed of cells of the immune system and 
connective tissue. It has been proposed that the 
communication between the neoplastic cell and their 
TME through soluble secreted factors or cell-cell 
contacts promotes tumor progression by interference 
with the function of cells of the immune system [9, 
10]. Even though a patient may be initially diagnosed 
with a tumor type indicative of a good prognosis, the 
influence of the microenvironment and the tumor 
crosstalk could change the course of the disease. 
Nowadays, the communication between cancer and 
immune cells has and is being extensively studied, 
with novel therapeutic drugs developed against 
immune checkpoint controls [11, 12]. Currently, the 
FDA has approved the use of Nivolumab and 
Ipilimumab, targeting PD-1 and CTLA-4 respectively, 
to treat melanoma [13]. The link between chronic 
inflammation and carcinogenesis was already 
proposed by Rudolf Virchow as early as 1863 [14] and 
in spite of the recent advances, little is known about 
the signaling pathways that link these processes and 
its participation in the prognosis of patients with 
breast cancer. For example, in inflammatory breast 
cancer (IBC), an aggressive form of breast cancer, 
overexpression of Her2 and NF-κB (nuclear factor 
kappa-light-chain-enhancer of activated B cells) is 
associated with a poor prognosis [15].  
NF-κB refers to a family of five different 
DNA-binding proteins which are key regulators of 
innate and adaptive immune responses. Furthermore, 
NF-κB is also involved in the regulation of multiple 
pathogenetically relevant processes in epithelial cells 
such as proliferation, angiogenesis, migration, 
invasion, and metastasis (all processes considered as 
hallmarks of cancer) through the activation of 
cytokines like IL-8 or metalloproteases (MMPs) [16, 
17]. These transcription factors are NF-κB1 
(p50/p105), NFκB2 (p52/p100), RelA (p65), RelB, and 
c-Rel; which can homo or hetero-dimerize to allow 
DNA binding and activate transcription [17]. NF-κB 
can be activated by multiple ligands, including 
cytokine receptors, PAMPs (Pathogen-Associated 
Molecular Patterns), physiological stress, TNF (Tumor 
Necrosis Factor), and members of the TNF receptor 
family such as CD40, and BAFF (B cell-activating 
factor of the TNF family). There are two pathways by 
which the signal is transduced: 1) the classical (also 
named canonical), and 2) the alternative or 
non-canonical pathway. Both pathways have in 
common that receptor activation induces the 
phosphorylation and subsequent degradation of IκB 
proteins (the NF-κB inhibitors), however, while the 
classical pathway mediates this effect through the IKK 
complex, the alternative pathway acts through NIK 
(NF-κB-inducing kinase) and IKKα [17-19]. Upon IκB 
degradation, NF-κB translocates to the nucleus to act 
as a transcription factor. Also, different NF-κB dimers 
represent canonical and non-canonical pathways, for 
instance, p50:p65 are common to classical activation 
and p52:RelB to the alternative pathway [17-19]. 
An active NF-κB pathway is decisive to explain 
the inflammatory profile of IBC, as well as the high 
metastatic potential of this form of breast cancer, 
through secretion of cytokines, growth factors, and 
proteases. An NF-κB transcriptional signature has 
been observed in IBC but also in ER-positive luminal 
breast cancers [20]. The NF-κB pathway has been 
associated with early events during oncogenesis [21]. 
In vitro data by Espinoza-Sánchez et al have suggested 
that the NF-κB pathway is a key regulator of 
intra-tumoral communication responsible for tumor 
cell plasticity in breast cancer [22]. In a cohort of 59 
patients with primary breast cancer, levels of 
phosphorylated p65 correlated with HER2 expression, 
tumor size, grade and presence of metastases [23, 24]. 
In a tissue microarray of 376 patients with invasive 
ductal breast cancer, Bennett et al demonstrated that 
the activation of the classical NF-κB pathway 
correlates with poor outcome [25]. However, so far, a 
comprehensive analysis of the impact of the classical 
and non-canonical NF-κB pathways is missing.  
In this study, to assess the relevance of the 
activity of key members and targets of the NF-κB 
pathway for relapse-free and overall survival of breast 
cancer patients, we performed Kaplan-Meier plot 
survival analysis using the online database 
www.kmplot.com/breastcancer [26]. This web-tool 
allows for the selection of patients, which can be 
filtered by receptors status, lymph node involvement, 
molecular classification, and others. We have found 
that the expression of members of the canonical and 
alternative NF-κB pathway influence prognosis in 
breast cancer patients independent from their 
classification (molecular, grade or LN status). 
Interestingly, IKKα, a common component of the 
canonical and alternative pathways emerges as a 
possible candidate to determinate the outcome of the 
patient as well as the downstream regulatory targets 
IL-8 and MMP-1 and may represent potential 
therapeutic targets, especially for IKKα in ER-positive 
tumors.  
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Material and methods  
Kaplan-Meier plots  
In order to analyze the prognostic value of a 
member of the NF-κB pathway in the relapse-free 
survival of patients with breast cancer, we used the 
publically available gene expression database Kaplan 
Meier plotter [27]. This database was established 
using gene expression data and survival information 
downloaded from Gene Expression Omnibus (GEO) 
[27] and contains patient samples from Memorial 
Sloan Kettering Cancer Institute, New York, USA; the 
Breast International Group (BIG) 1-98 that includes 
patients of different European and Latin American 
countries, and the USA; Radboud University 
Nijmegen Medical Centre, Nijmegen, The 
Netherlands; Technical University Munich, Germany; 
National Cancer Institute, Bari, Italy; Institute of 
Oncology, Ljubljana, Slovenia; Department of 
Obstetrics, Gynecology of the Johannes Gutenberg 
University Mainz, Germany; John Radcliffe Hospital, 
Oxford, United Kingdom; Guys Hospital, London, 
United Kingdom; Uppsala University Hospital, 
Uppsala, Sweden; Institut Gustave Roussy, Villejuif, 
France; Karolinska Institute, Stockholm, Sweden; 
Centre Rene´ Huguenin, Saint-Cloud, France; 
Netherlands Cancer Institute, Netherlands; Stanford 
University, USA; National University Hospital, 
Singapore; and Erasmus Medical Center, Rotterdam, 
The Netherlands [27-42]. Currently, this program has 
relapse-free survival data of 3,955 patients and overall 
survival data of 1,402 patients downloaded from GEO 
and EGA (European Genome-Phenome Archive). The 
package "survival" was used in the R programming 
environment to plot Kaplan–Meier survival curves 
and the number-at-risk [27]. The 'median' cutoff was 
used to split patient groups into high and low 
expression cohorts and these were compared using 
Cox regression analysis. Patients were stratified by ER 
status, HER2 status (n=1,872), lymph node status, 
molecular classification, Pietenpol subtype, and 
grading. We studied some components of the NF-κB 
pathway and visualized the correlation to survival by 
drawing Kaplan-Meier survival plots. The Affymetrix 
IDs utilized for the genes were: 209666_s_at-IKKα, 
209341_s_at-IKBKB, 209239_at-p50/NFKB1, 201783_ 
s_at-p65/RELA, 205192_at-NIK, 207535_s_at-p52, 
205205_at-RELB, 202859_x_at-IL-8, 205207_at-IL6, and 
204475_at-MMP-1. Finally, the False Discovery Rate 
(FDR) was computed to correct for multiple 
hypothesis testing. The percentage of patients 
tabulated in table 1 is a result from 37 different 
datasets, 35 from GEO (GSE1456, GSE2034, GSE2990, 
GSE3494, GSE4922, GSE6532, GSE7390, GSE11121, 
GSE12093, GSE5327, GSE9195, GSE16391, GSE12276, 
GSE2603, GSE17705, GSE21653, GSE16446, GSE17907, 
GSE19615, GSE20685, GSE20711, GSE26971, 
GSE31448, GSE31519, GSE20194, GSE20271, 
GSE32646, GSE18728, GSE23988, GSE41998, 
GSE16716, GSE42568, GSE45255, GSE37946, GSE4611) 
and 2 from EGA (E-MTAB-365, E-TABM-43). 
Cell culture  
All human breast cancer cell lines except 
SUM149 were purchased from ATCC/LGC 
Promochem (Wesel, Germany). T47D, MDA-MB-453, 
MDA-MB-468, MDA-MB-231, and SKBR3 cells were 
maintained in DMEM containing 10% FCS, 1% 
glutamine and 1% penicillin/streptomycin in a 
humidified atmosphere of 7.5% CO2 at 37°C. MCF-7 
cells were maintained in RPMI containing 10% FCS, 
1% glutamine and 1% penicillin/streptomycin in a 
humidified atmosphere of 5% CO2 at 37°C. BT474 cells 
were maintained in RPMI containing 20% FCS, 1% 
glutamine and 1% penicillin/streptomycin and 0.01 
mg/ml insulin in a humidified atmosphere of 5% CO2 
at 37°C. The inflammatory breast cancer cell line 
SUM149 (a kind gift from Dr. Bonnie Sloane, Wayne 
State University, Detroit, MI, USA) was maintaining 
in HAM´s containing 10% FCS, 1% glutamine and 1% 
penicillin/streptomycin in a humidified atmosphere 
of 7.5% CO2 at 37°C. To activate NF-κB, BrC cells were 
plated at a density of 20,000 cells in 8 well chamber 
slides (Nunc, Wiesbaden, Germany) to perform 
immunofluorescence microscopy (IF). Once cells 
attached to the plate, supernatants were discarded, 
cells were rinsed with PBS, and then stimulated with 
40 ng/mL of human recombinant human TNF-α 
(R&D Systems, Wiesbaden, Germany.) in culture 
medium for 40 min., followed by processing for 
immunofluorescence microscopy as indicated below.  
Quantitative real-time PCR  
Total RNA was isolated from the cultured 
human breast cancer cells MCF-7, T47D, BT474, 
SKBR3, MDA-MB-453, MDA-MB-468, MDA-MB-231, 
and SUM149 using the innuPREP RNAMini Kit 
(Biometra, Göttingen, Germany) according to the 
manufacturer's instructions and RNA was reverse 
transcribed into cDNA using the First Strand cDNA 
Synthesis Kit (Thermo Fisher, Schwerte, Germany), 
random hexamer primers and M-MuLV reverse 
transcriptase. Quantitative real-time PCR was 
conducted in triplicates for each gene of interest using 
SYBR Green dye (Thermo Fisher) and gene expression 
levels were measured in an ABI PRISM 7300 
SequenceDetection System (Thermo Fisher). For 
transcriptional analysis, the RT-PCR products were 
quantified by the fluorescent method using the 2−ΔCt 
value. To normalize gene expression, Cycle threshold 
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(Ct) values from each sample were normalized with 
its corresponding β-ACTIN Ct. Normalized values 
were converted to log base 2 before data was 
evaluated by statistical analysis. Melting curve 
analysis was performed to confirm specific product 
amplification. Primer sequences were confirmed by 
NCBI BLAST analysis and are listed in the 
supplementary file Table S8.  
Confocal immunofluorescence microscopy 
TNF-α-stimulated or unstimulated cell lines 
grown on chamber slides were fixed with 3.7% 
PBS-buffered formaldehyde and permeabilized with 
PBS/0.1% Triton-X100. Nonspecific binding was 
blocked with PBS/1% Aurion BSA-c (DAKO, 
Glostrup, Denmark). Coverslips were subsequently 
incubated for 1 hr with rabbit anti-NF-κB p65 (C22B4) 
mAb (Cell Signaling Technology, Frankfurt a.M., 
Germany) diluted 1:1,000 in PBS/1% Aurion BSA, 
followed by 3 x 5 min washes with PBS. Subsequently, 
the samples were incubated with Alexa Fluor 488 
conjugated donkey anti-rabbit antibody (Invitrogen, 
Karlsruhe, Germany) diluted 1:500, in PBS/1% 
Aurion BSA-c. for 30 min. Samples were washed 2x 
for 5 min in PBS, stained with 300 nM DAPI (Sigma, 
Deisenhofen, Germany) for 1 min, followed by a brief 
wash with PBS and slide mounting, Slides were 
analyzed with a confocal microscope (Axioskop; Carl 
Zeiss, Göttingen, Germany) with × 40 magnification 
and a 0.75 numerical aperture oil immersion objective. 
Protein interaction network analysis 
STRING v11 (http://string-db.org/) was used to 
generate in silico protein interaction networks for the 
gene products that we analyzed in KMplot, IKKα 
(CHUK), IKBKB, p50/NFKB1, p65/RELA, NIK 
(MAP4K4), p52 (NFKB2), RELB, IL-8 (CXCL8), IL6, 
and MMP-1. All interactions are predicted with a high 
confidence threshold of 0.700, and all active predictive 
methods were allowed. For the enrichment analysis, 
STRING implements well-known classification 
systems such as Gene Ontology (GO) and KEGG 
(Kyoto Encyclopedia of Genes and Genomes) [43]. 
Statistical analysis.  
For survival analysis, in the R statistical 
environment, we utilized the Kaplan-Meier-Plotter 
database via the statistical package "survival" to 
calculate Kaplan–Meier survival curves and the 
number-at-risk. Furthermore, the hazard ratio (and 
95% confidence intervals) and log-rank P were 
calculated for each gene [27]. The FDR was computed 
using the brainwaver library in R. For analysis of 
qPCR results, the Prism software version 5.01 
(GraphPad) was used for statistical analysis. A 
oneway analysis of variance (ANOVA) test with the 
Tukey as a post hoc test was applied to more than two 
groups of data, and the non-parametric 
Kruskal-Wallis test with Dunnett's as post hoc test 
was applied to more than two groups in case the data 
lack normality and/or homogeneity of variance. 
Significant P-values are indicated as follows: ≤0.05 by 
one asterisk *, ≤0.01 by two asterisks ** and ≤ 0.001 by 
three asterisks ***.  
Results  
Expression of IKKα is associated with poor 
relapse-free survival, while representative 
genes from the alternative pathway are 
associated with better relapse-free and overall 
survival in breast cancer patients.  
We analyzed the correlation between the 
expression of common and unique members of both 
canonical and alternative NF-κB pathways and some 
of their transcriptional targets with the relapse-free 
survival (RFS) and overall survival (OS) of breast 
cancer patients. A total of 3,951 for RFS and 1,402 for 
OS patients without any classification were analyzed 
using the online database www.kmplot.com/ 
breastcancer, Table 1 displays the clinicopathological 
characteristics of the investigated patients.  
 
Table 1. Clinico-pathological characteristics of the patients 
investigated in the present study 
Parameter Cohort Proportion of patients 
Array platform HGU133A 52.1% 
HGU133A plus 2.0 47.9% 
ER status ER-positive 76.4% 
ER-negative 23.6% 
HER2 status HER2 positive 17.7% 
HER2 negative 82.3% 
Lymph node status Node positive 39.2% 
Node negative 60.8% 
Grade Grade 1 14.8% 
Grade 2 42.3% 
Grade 3 42.8% 
Molecular subtype 
(StGallen) 
TNBC 17.1% 
Luminal A 48.6% 
Luminal B 27.7% 
HER2 positive 6.5% 
Molecular subtype 
(Pietenpol) 
Basal-like 1 19.2% (within TNBC) 
Basal-like 2 7.8% (within TNBC) 
Immunomodulatory 23.4% (within TNBC) 
Mesenchymal 18.4% (within TNBC) 
Mesenchymal stem-like 9.2% (within TNBC) 
Luminal androgen-receptor 22% (within TNBC) 
Age Mean 53.6 years 
Median 53 years 
Range 24-93 years 
Relapse-free survival Follow-up time (months) 72.8+/-46.6 
The proportion of events 
(relapse) 
32% 
Overall survival Follow-up time (months) 84.8+/-47.8 
The proportion of events 
(death) 
25% 
 
Table 2 shows the HR (Hazard ratio) and P 
values of 10 genes: IKKβ, p50 and p65 from the 
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canonical pathway; NIK, p52, and RELB from the 
alternative pathway; IKKα which is common to both 
canonical and non-canonical pathways, and IL-8, IL-6, 
MMP-1 as downstream targets controlled by these 
pathways. We observed that only IKKα correlates with 
poor RFS in breast cancer patients (HR = 1.2; P = 
0.0012) (Figure 1A), we did not find a correlation of 
this gene with the OS (Table 2). In contrast IKKβ and 
p50 from the canonical pathway and the expression of 
NIK and RELB from the alternative pathway 
correlated with better RFS and OS in all patients (HR 
= <1, P = <0.05) (Table 2 and Figure 1B). The 
expression of p65 HR = 0.83; P = 0.00088 (Figure 1A) 
and p52 HR = 0.8; P = 5.7e-05 (Table 2) correlated also 
with better RFS, but not with OS. Since inflammatory 
factors, chemokines and some proteases are important 
targets of the NF-κB pathway [17, 44, 45], we analyzed 
the expression of IL-8, IL-6, and MMP-1 (also factors 
associated with the breast cancer tumor 
microenvironment and progression [46]) and 
correlated them with the RFS and OS of the patients. 
IL-8 and MMP-1 were associated with poor RFS and 
OS, IL-8 with a HR = 1.29 (P = 4.1e-06) regarding RFS 
and HR = 1.52 (P = 0.00013) regarding OS; and MMP-1 
with a HR = 1.78 (P = <1E-16) regarding RFS and HR = 
1.6 (P = 1.6e-05) regarding OS (Figure 1C and Table 
2). IL-6 (HR = 0.81, P = 0.00021) was associated with a 
better RFS but, not with OS (Table 2). Altogether, 
these data support that expression of genes related to 
both the canonical and alternative pathways of NF-κB 
influence the prognosis of breast cancer patients.  
Members of the canonical and alternative 
NF-κB pathway are associated with better 
relapse-free survival of breast cancer patients 
independent of estrogen receptor status.  
We next analyzed if there was a correlation 
between members of the NF-κB pathway and the RFS 
and OS of breast cancer patients stratified by estrogen 
receptor status. A total of 3,082 breast cancer patients 
with RFS data and 1,044 with OS data and estrogen 
receptor (ER) positive status; and 869 (RFS) and 358 
(OS) patients with ER-negative status were analyzed 
(Table 3). Again we could observe that IKKα 
correlated with poor RFS only in ER-positive patients 
(HR = 1.2; P = 0.0051), but we did not find an 
association with OS (Figure 2A and Table 3). In 
contrast, p50, p65, p52, NIK, RELB and, IL-6 were 
associated with better RFS in all patients regardless of 
their ER status (Figure 2B, C, and D, Table 3). Also, 
p50 and RELB correlated with better OS in both 
ER-positive and ER-negative patients (Table 3). The 
expression of IKKβ was associated with better RFS 
only in ER-positive tumors (HR = 0.74; P = 5.9e-06). 
The expression of IL-8 was associated with poor RFS 
and OS in patients with ER-positive tumors (HR = 
1.18; P = 0.011; HR = 1.36; P = 0.018, respectively) and 
also correlated with poor RFS in ER-negative tumors 
(HR = 1.29; P = 0.018) (Figure 2E and Table 3). 
Interestingly, MMP-1 was associated with poor RFS 
and OS only in patients with ER-positive tumors (HR 
= 1.7; P = 5.6e-16 and HR = 1.61; P = 0.00027, 
respectively) (Figure 2F and Table 3).  
 
Table 2. Correlation between members of the NF-κB and 
survival of breast cancer patients.  
 Genes Relapse-free survival 
(n=3951) 
Overall survival (n=1402) 
HR 95% CI  P value  HR 95% CI  P value 
 IKKβ  0.62 (0.62 - 0.77)  1.9e-11*  0.76 (0.61 – 
0.94) 
0.011* 
Classical 
pathway 
p50/NFKB1  0.63 (0.57 - 0.71)  3.3e-16*  0.67 (0.54 – 
0.83) 
0.00025* 
 p65/RELA 0.83 (0.75 - 0.93) 0.00088* 1 (0.81 – 1.24) 1 
Alternative 
pathway 
NIK  0.61 (0.54 - 0.68)  <1E-16*  0.64 (0.52 – 0.8) 7.1e-05* 
p52  0.8 (0.72 – 0.89)  5.7e-05*  0.87 (0.7 – 1.07) 0.19 
RELB  0.69 (0.62 - 0.78)  6.9e-11*  0.66 (0.53 – 
0.82) 
0.00019* 
Both 
pathways 
IKKα 1.2 (1.07 - 1.33) 0.0012* 1.19 (0.96 – 
1.48) 
0.11 
NF-κB 
target genes 
IL-8  1.29 (1.16 - 1.44)  4.1e-06*  1.52 (1.22 – 
1.88) 
0.00013* 
IL-6  0.81 (0.73 - 9.1)  0.00021*  0.92 (0.75 – 
1.15) 
0.48 
MMP-1  1.78 (1.59 - 1.98)  <1E-16*  1.6 (1.29 – 1.99) 1.6e-05* 
Bold typing of P-values indicates a significant association (P<0.05). An asterisk 
indicates an FDR below 10%. 
 
We also wanted to analyze patients based on the 
Luminal A molecular classification, which is based on 
the expression of the estrogen and progesterone 
receptor and is associated to a better outcome in 
breast cancer patients [2, 3]. A total of 1,933 patients 
with RFS data and 611 with OS data were analyzed. 
We could corroborate that even classifying patients in 
this way, the expression of IKKα (HR = 1.2; P = 0.039), 
IL-8 (HR = 1.2; P = 0.035), and MMP-1 (HR = 1.89; P = 
4.6e-13) correlates with poor RFS; MMP-1 expression 
also correlated with poor OS (Table S1). Again, IKKβ, 
p50, p65, p52, NIK, RELB and, IL-6 were associated 
with better RFS; p50 and RELB were associated with 
better OS (Table S1). These results suggest that the 
expression of several members of the canonical or 
alternative NF-κB pathway has a positive prognostic 
value in breast cancer that is independent of estrogen 
receptor status.  
The association between the expression of 
members of the canonical and alternative 
NF-κB pathways and good prognosis in breast 
cancer does not depend on the molecular 
classification.  
We next wanted to evaluate if the association of 
genes of the NF-κB pathway with a good prognosis in 
breast cancer patients was associated with a particular 
molecular subtype of the disease.  
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Figure 1. The prognostic value of the expression of genes associated with the NF-κB pathway. Kaplan-Meier relapse-free survival curves are plotted for all breast 
cancer patients (n=3951). A) IKKα, a common component of the canonical and alternative pathways and p65 from the classical NF-κB pathway. B) Genes of the alternative NF-κB 
pathway. C) Targets genes of the NF-κB pathway. Log-rank p values and hazard ratios (HRs; 95 % confidence interval in parentheses) are shown. The desired Affymetrix IDs are: 
209666_s_at-IKKα, 201783_s_at-p65/RELA, 205192_at-NIK, 205205_at-RELB, 202859_x_at-IL-8, and 204475_at-MMP-1.  
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Figure 2. The prognostic value of the expression of genes associated with the NF-κB pathway based on ER (estrogen receptor) status. Kaplan-Meier 
relapse-free survival curves are plotted for breast cancer patients with ER+ (n=3082) and ER- (n=869), and the expression of A) IKKα, B) p65, C) NIK, D) RELB, E) IL-8, and F) 
MMP-1. Log-rank p values and hazard ratios (HRs; 95 % confidence interval in parentheses) are shown.  
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Table 3. Correlation between members of the NF-κB and estrogen receptor (ER) status of breast cancer patients.  
Genes  ER status  Relapse-free survival  Overall survival  
Cases  HR 95% CI  P value  Cases  HR 95% CI  P value  
Classical pathway IKKβ  Positive  3082  0.74 (0.65 – 0.85)  5.9e-06* 1044  0.78 (0.6 – 1.01)  0.057  
Negative  869  0.85 (0.69 – 1.05)  0.14 358  0.9 (0.61 – 1.33)  0.61  
p50/NFKB1  Positive  3082  0.61 (0.54 – 0.69)  4.7e-14* 1044  0.69 (0.53 – 0.89)  0.0046*  
Negative  869  0.67 (0.54 – 0.82)  0.00016* 358  0.58 (0.38 – 0.87)  0.0072  
p65/RELA  Positive  3082  0.86 (0.75 – 0.97)  0.017* 1044  1.05 (0.81 – 1.36)  0.69  
Negative  869  0.74 (0.6 – 0.91)  0.0049* 358  0.82 (0.55 – 1.21)  0.32  
Alternative pathway  NIK  Positive  3082  0.63 (0.55 – 0.72)  1.4e-12* 1044  0.82 (0.63 – 1.06)  0.12  
Negative  869  0.56 (0.45 – 0.69)  5.3e-08* 358  0.54 (0.36 – 0.81)  0.0022 * 
p52  Positive  3082  0.76 (0.67 – 0.86)  2.5e-05* 1044  0.96 (0.75 – 1.24)  0.77  
Negative  869  0.68 (0.55 – 0.84)  3e-04* 358  0.68 (0.46 – 1.01)  0.053  
RELB  Positive  3082  0.71 (0.62 – 0.81)  1.4e-07* 1044  0.76 (0.59 – 0.98)  0.037  
Negative  869  0.55 (0.44 – 0.68)  3.8e-08* 358  0.47 (0.32 – 0.71)  0.00026*  
Both pathways IKKα  Positive 3082 1.2 (1.06 – 1.36) 0.0051* 1044 1.09 (0.84 – 1.41) 0.52 
Negative 869 1.09 (0.89 – 1.35) 0.4 358 1.07 (0.72 – 1.58) 0.74 
NF-κB  
target genes  
IL-8  Positive  3082  1.18 (1.04 – 1.34)  0.011* 1044  1.36 (1.05 – 1.76)  0.018  
Negative  869  1.29 (1.04 – 1.59)  0.018 358  1.28 (0.86 – 1.89)  0.22  
IL-6  Positive  3082  0.78 (0.68 – 0.88)  0.00012* 1044  0.96 (0.74 – 1.25)  0.76  
Negative  869  0.77 (0.63 – 0.96)  0.018 358  1.18 (0.8 – 1.75)  0.4  
MMP-1  Positive  3082  1.7 (1.49 – 1.93)  5.6e-16* 1044  1.61 (1.24 – 2.09)  0.00027*  
Negative  869  1.04 (0.84 – 1.28)  0.71 358  1.1 (0.75 – 1.63)  0.62  
Bold typing of P-values indicates a significant association (P<0.05). An asterisk indicates an FDR below 10%. 
 
Since the canonical and alternative pathway 
have been associated with basal or triple-negative 
breast cancer (TNBC), which have the worst outcome 
in patients [47-50], we analyzed all the 
aforementioned genes in 618 patients with RFS and 
241 with OS data classified with the intrinsic basal 
molecular subtype. Our results shown that only the 
expression of p50 from the canonical pathway was 
associated with better RFS with an HR = 0.65; P = 
0.00099. In addition, the expression of all the genes 
associated with the alternative pathway correlated 
with better RFS: NIK HR = 0.54; P = 2.4e-06, p52 HR = 
0.69; P = 0.0039 and RELB HR = 0.54; P = 1.8e-06. NIK 
and RELB also were associated with better OS. Of the 
target genes analyzed, IL-8 was associated with poor 
RFS with an HR = 1.46; P = 0.0035. MMP-1 expression 
was associated with poor OS (HR = 1.65; P = 0.048), 
but not with RFS (Table S2).  
In 2011, Pietenpol and coworkers classified 
TNBC into 6 subtypes, among them the 
immunomodulatory subtype which was enriched for 
gene ontologies of immune cell-related processes [51]. 
Due to the strong relationship between the NF-κB 
pathway and immune processes we analyzed the 
relationship between this pathway and RFS and OS of 
breast cancer patients classified as the 
immunomodulatory subtype (n= 203 with RFS data 
and n=100 with OS data). We found that p50 with a 
HR = 0.51; P = 0.033 and NIK HR = 0.51; P = 0.033 
correlated with better RFS in the patients. Not 
surprisingly, we observed that IL-8 was associated to 
poor RFS and OS (HR = 2; P = 0.024, HR = 4.11; P = 
0.007; respectively) and we note that it had the highest 
HR using this classification. Interestingly, MMP-1 
correlated with better RFS (HR = 0.49; P = 0.02) (Table 
S3). Furthermore, we analyzed the Pietenpol 
Basal-like 1 classification in 171 breast cancer patients 
with RFS data (panel A) and 58 with OS data (panel 
B). Of all the genes analyzed, only NIK has an 
association with better RFS and OS (Supplementary 
Figure S1), the other genes had no association with 
RFS or OS (data not shown).  
The expression of members of the canonical 
and alternative NF-κB pathway correlates with 
better relapse-free survival of breast cancer 
patients and is independent of their lymph 
node status.  
We next determined the correlation of the NF-κB 
pathway and selected targets with nodal status, 
analyzing a total of 1,133 breast cancer patients with 
lymph node (LN) positive and 2020 with lymph 
node-negative status for RFS (Table 4). Although the 
HR of IKKα and p65 has a high score, its expression 
was not significantly related to the RFS of patients 
regardless of nodal status (Table 4). However, the 
expression of IKKβ (LN-positive: HR = 0.63, P = 
5.5e-06; LN-negative: HR = 0.81, P = 0.017), p50 
(LN-positive: HR = 0.75, P = 0.004; LN-negative: HR = 
0.73, P = 0.00019), NIK (LN-positive: HR = 0.7, P = 
0.00032; LN-negative: HR = 0.78, P = 0.0048), p52 
(LN-positive: HR = 0.67, P = 6.8e-05; LN-negative: HR 
= 0.83, P = 0.028), and RELB (LN-positive: HR = 0.77, P 
= 0.0092; LN-negative: HR = 0.83, P = 0.029) correlated 
with better RFS in all patients independent of their LN 
status (Figure 3A-D, Table 4). In samples for which 
OS data were available, (LN-positive n = 313 and 
LN-negative n = 594), IKKβ was associated with better 
OS in LN-positive patients. The same association was 
seen for p50 and NIK in LN-negative patients (Table 
4).  
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Figure 3. The prognostic value of the expression of genes associated with the NF-κB pathway based on the Lymph node status. Kaplan-Meier relapse-free 
survival curves are plotted for breast cancer patients with Lymph+ (n=1133) and Lymph- (n=2020), and the expression of A) IKKβ, B) p50, C) NIK, D) RELB, E) IL-8, and F) MMP-1. 
Log-rank p values and hazard ratios (HRs; 95 % confidence interval in parentheses) are shown.  
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Table 4. Correlation between members of the NF-κB and lymph node (LN) status of breast cancer patients.  
  
Genes  
 
LN status  
 Relapse-Free survival  Overall survival 
Cases  HR 95% CI  P value  Cases  HR 95% CI  P value  
Classical pathway IKKβ Positive 1133 0.63 (0.52 – 0.77) 5.5e-06* 313 0.65 (0.44 – 0.96) 0.031 
Negative  2020  0.81 (0.69 – 0.96)  0.017  594  0.71 (0.48 – 1.03)  0.066  
p50/NFKB1  Positive  1133  0.75 (0.62 – 0.91)  0.004*  313  0.73 (0.49 – 1.09)  0.12  
Negative  2020  0.73 (0.61 – 0.86)  0.00019*  594  0.62 (0.42 – 0.9)  0.012  
p65/RELA  Positive  1133  0.91 (0.75 – 1.11)  0.34  313  0.98 (0.67 – 1.45)  0.93  
Negative  2020  1 (0.85 – 1.19)  0.97  594  0.73 (0.5 – 1.08)  0.11  
Alternative 
pathway  
NIK  Positive  1133  0.7 (0.57 – 0.85)  0.00032*  313  0.89 (0.6 – 1.31)  0.55  
Negative  2020  0.78 (0.66 – 0.93)  0.0048  594  0.55 (0.37 – 0.82)  0.0026*  
p52  Positive  1133  0.67 (0.55 – 0.82)  6.8e-05*  313  0.82 (0.55 – 1.21)  0.32  
Negative  2020  0.83 (0.7 – 0.98)  0.028  594  1.16 (0.8 – 1.69)  0.43  
RELB  Positive  1133  0.77 (0.63 – 0.94)  0.0092*  313  0.74 (0.5 – 1.09)  0.13  
Negative  2020  0.83 (0.7 – 0.98)  0.029  594  0.74 (0.51 – 1.07)  0.11  
Both pathways IKKα Positive 1133 0.89 (0.73 – 1.08) 0.24 313 0.74 (0.5 1.09) 0.13 
Negative 2020 1.05 (0.89 – 1.24) 0.59 594 1.12 (0.76 – 1.63) 0.57 
NF-κB  
target genes  
IL-8  Positive  1133  1.33 (1.09 – 1.62)  0.0043*  313  1.19 (0.81 – 1.76)  0.37  
Negative  2020  1.35 (1.14 – 1.59)  0.00053*  594  1.18 (0.81 – 1.71)  0.39  
IL-6  Positive  1133  1.03 (0.85 – 1.25)  0.78  313  1.07 (0.73 – 1.58)  0.73  
Negative  2020  0.97 (0.82 – 1.15)  0.73  594  0.96 (0.66 – 1.41)  0.84  
MMP-1  Positive  1133  1.67 (1.37 – 2.03)  3.5e-07*  313  1.13 (0.76 – 1.66)  0.55  
Negative  2020  1.63 (1.37 – 1.93)  1.8e-08*  594  2 (1.36 – 2.92)  0.00028*  
Bold typing of P-values indicates a significant association (P<0.05). An asterisk indicates an FDR below 10%. 
 
Interestingly, the expression of important targets 
of the NF-κB pathway such as IL-8 and MMP-1 has a 
poor RFS in the patients regardless of nodal status 
(Figure 3E, F). Of these genes, only MMP-1 correlated 
with poor OS in LN-negative tumors (Table 4). The 
grade of a tumor is an important parameter to analyze 
the treatment and prognosis of a breast cancer patient, 
frequently associated with LN status [52]. Analyzing 
the patients according to grade 3 status (n = 903), the 
expression of p50, NIK, p52, and RELB correlated with 
better RFS (Table S4). Analyzing the total of patients 
with available OS data (n=503), the expression of NIK 
and RELB were associated with better OS (Table S4).  
The expression of NIK, RELB, IL-8, and MMP-1 
are associated with the basal subtype in human 
breast cancer cell lines.  
In the current study, we report that the 
expression of a majority of genes related to the NF-κB 
pathway is associated with better RFS in breast cancer 
patients. However, we do not know if the expression 
of these genes largely stems from the tumor cells or 
from the cells of their microenvironment (e.g. 
cancer-associated fibroblasts, endothelial cells, 
pericytes, the immune cell infiltrate, etc.). Therefore, 
we assessed the relative expression of IKBKB, p50, p65, 
NIK, RELB, IL-8, and MMP-1 using quantitative 
real-time PCR (qPCR) in seven breast cancer cell lines 
classified according to their molecular subtype: 
Luminal, MCF-7 and T47D; Her2, BT474 and SKBR3, 
and Basal, MDA-MB-453, MDA-MB-468 and 
MDA-MB-231 [53], and the inflammatory breast 
cancer (IBC) cell line SUM149. The qPCR analysis 
showed two noteworthy results: 1) even when the cell 
lines were classified in the same molecular subtype, 
the relative expression (represented by 2-ΔCt) of the 
genes varied among them (consistent with previous 
data [22]) and 2) in the luminal cell line T47D, almost 
all genes were highly expressed and significantly 
different from the other cell lines (Figure 4). 
Regardless of T47D, we observed that RELB and IL-8 
are more highly expressed in the basal and in the IBC 
line compared with the Luminal and Her2 cell lines. 
IL-8 showed a particularly high degree of 
overexpression in the IBC cell line. p50 and NIK were 
highly expressed in the basal cell line MDA-MB-231 
and in the IBC cell line SUM-149. Interestingly, 
MMP-1 was expressed only in the basal cell line 
MDA-MB-231. We did not find a significant difference 
in the relative expression of IKBKB and p65 in all cell 
lines (Figure 4). These results suggest that the 
expression of alternative NF-κB pathway-related 
genes is more strongly associated with basal subtypes 
which have a poor outcome [3]. To determine if the 
NF-κB pathway can be activated in the cell lines, we 
tested whether the p65 subunit of NFκB was present 
in the cytoplasm (inactive) or nucleus (active) in all 
breast cancer cell lines in which PCR was performed, 
by confocal immunofluorescence microscopy. We 
found that p65 had a cytoplasmic localization in all 
cell lines, which suggests that the pathway is inactive 
under our routine cell culture conditions. However, in 
the T47D, SKBR3, MDA-MB-468, and MDA-MB-231 
cell lines, a few cells showed nuclear localization of 
p65 (Figure 5, upper panel, white inserts). To 
simulate the activation of the pathway by cells of the 
tumor microenvironment, we treated all cell lines 
with 40 ng/mL of TNF-α (a known factor for 
activating the NFκB pathway [54]) for 40 min. TNF-α 
stimulation resulting in a nuclear p65 translocation in 
all cell lines tested, indicating that the pathway was 
activated (Figure 5, lower panel). We observed 
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nuclear p65 translocation already at 10 min TNF-α 
treatment (Supplementary Figure S2) which 
persisted for the maximal treatment duration of 40 
min (data not shown). These data suggest that some of 
the cells have a basal low activation of NF-κB that 
could be further activated in the tumor 
microenvironment.  
Functional enrichment analysis for NF-κB 
related proteins 
We used the STRING bioinformatic tool to find 
biological processes associated with the gene products 
that we analyzed for their prognostic impact on breast 
cancer, namely IKKα (CHUK), IKBKB, p50/NFKB1, 
p65/RELA, NIK (MAP4K4), p52 (NFKB2), RELB, IL-8 
(CXCL8), IL6, and MMP-1. The STRING analysis 
showed that a) all analyzed proteins are highly 
interconnected, b) the proteins of the NF-κB pathway 
(IKKα (CHUK), IKBKB, p50/NFKB1, p65/RELA, NIK 
(MAP4K4), p52 (NFKB2), and RELB) have close 
interactions with TNF and cAMP-response 
element-binding protein (CREBBP), and regulate IL-8 
(CXCL8), IL-6 and MMP-1. c) NF-κB regulates its own 
inhibitors of the IκB family such as IKKG (IKKγ) and 
NFKB1A (IκBα), d) the NF-κB transcriptional target 
IL-8 (CXCL8) is associated with CXCR2 (IL-8 receptor) 
and MMP-1, while IL-6 is associated with IL-6 
receptor (IL-6R), IL-6 signal transducer (IL6ST), 
 
 
Figure 4. Relative expression of NF-κB pathway-related genes in breast cancer cell lines. IKBKB, p50, p65, NIK, RELB, IL-8, and MMP-1 gene relative expression was 
quantified by qRT-PCR in 7 breast cancer cell lines representative of the luminal, basal and Her2-positive subtype, and in one inflammatory breast cancer (IBC) cell line. Individual 
experiments were normalized against β-ACTIN and relative expression was represented by 2-ΔCt. Data represent the mean ± SEM (standard error of the mean) from one 
experiment in triplicates; *P<0.05, **P<0.01 and ***P<0.001.  
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STAT3 and the interleukins IL-4 and IL-10 (Figure 
6A). We then used GO enrichment analysis to assess 
molecular function, cellular component and biological 
process associated with the analyzed proteins. The 10 
most significantly enriched terms (p<0.05) in each 
category are presented in Figure 6B and Table S5. 
Interestingly, KEGG pathway analysis revealed 
enriched pathways linked to inflammation, cancer, 
cancer infection origin, miRNAs in cancer and 
proteoglycans in cancer (Figure 6C and Table S6). In 
addition, STRING developed a statistical co-citation 
analysis across a large number of scientific texts in 
PubMed [43]. Table S7 shows the 10 most 
significantly enrichments, almost all of which are 
associated with cancer.  
Taking into account all these data, our analysis 
suggests that the expression of specific members of 
the canonical and alternative NF-κB pathway (IKKβ, 
p50/NFKB1, p65/RELA, NIK, p52, RELB, and IL-6) are 
associated with a better prognosis in breast cancer 
patients regardless of their classification (molecular, 
grade or LN status). Moreover, IKKα, IL-8, and MMP-1 
expression are associated with poor survival. These 
genes may represent potential therapeutic targets, 
especially IKKα in ER-positive tumors and IL-8 in the 
immunomodulatory subtype of TNBCs.  
Discussion  
In the present study, the expression of key 
members of both the canonical and alternative NF-κB 
pathway and selected downstream targets were 
analyzed to establish if there was a link between their 
expression at the transcriptional level and RFS and OS 
in a large cohort of breast cancer patients. To this 
purpose, we used the online “Kaplan-Meier plotter” 
database that allows a real-time analysis to evaluate 
the prognostic value of those genes in breast cancer. 
The authors of this tool have combined raw data from 
several studies to create a single dataset observing 
that the statistical power was highly increased [27]. 
Before their study in breast cancer, no tool like this 
was publically available to estimate the prognostic 
value of a specific gene in a large cohort of clinical 
patients. Now, this tool has a large number of patients 
with ovarian, lung, liver and gastric cancer with 
relapse-free and overall survival data and also 
miRNA expression in breast and liver cancer 
(http://kmplot.com/analysis/index.php?p=backgro
und) [27]. We think that this is a powerful tool to 
study specific genes relating them to the prognostic of 
cancer patients.  
 
 
 
Figure 5. TNF-α-induced activation of the NF-κB pathway in breast cancer cell lines. Cells were cultured under control conditions (upper panel) or after 20 min. 
stimulation with 40 ng/ml TNF-α (lower panel), followed by immunostaining for p65 (green fluorescence) and DAPI nuclear staining (blue). The upper panel shows the analysis 
of the constitutive cellular localization of p65 in all cell lines. Under control conditions, p65 largely localizes to the cytoplasm. Inserts show magnified areas of rare individual cells 
characterized by nuclear localization marked with white arrows in the overview panels. The lower panel shows cells after TNF-α stimulation, which induced the nuclear 
translocation of p65 in all cells studied. Representative images of 20 min of incubation with TNF-α are shown. Original magnification 400X. 
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Figure 6. Network of NF-κB protein interactors. A) STRING database output depicting functional and physical interactors of the NF-κB related proteins, IKKα (CHUK), 
IKBKB, p50/NFKB1, p65/RELA, NIK (MAP4K4), p52 (NFKB2), RELB, IL-8 (CXCL8), IL6, and MMP-1 obtained from http://string-db.org/. The ten NF-κB related proteins are 
highlighted in red boxes. B) GO (gene ontology) analysis of the NF-κB related proteins. The 10 most significantly (p<0.05) enriched GO terms in molecular function (green), 
cellular component (blue), and biological process (red) branches are presented. C) KEGG pathway analysis. All the adjusted statistically significant values of the terms were 
negative 10-base log-transformed. 
 
Signaling pathways are one of the most 
important players in the normal development of the 
cell. They control cell growth and differentiation, a 
process that is inevitably altered in cancer. There are 
signaling pathways associated with specific processes 
such as the TGF-β (transforming growth factor-β) 
pathway associated with the epithelial to 
mesenchymal transition, a process linked to 
malignancy [55]. However, signaling pathways form 
extensive networks interconnected with each other 
that allow important functions in the normal and 
cancerous cells [56]. For example, the induction of 
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late-stage tumor progression is dependent on the 
cooperation between Ras- and TGF-β–signaling 
pathways and this also depends critically on NF-κB 
activity [57]. Chronic infection and inflammation are 
highly oncogenic, and the NF-κB signaling pathway is 
linked to both processes [17].  
In this study, we found that the expression of 
IKKα (associated with both the canonical and 
alternative NF-κB pathway) and the NF-κB 
transcriptional targets IL-8 and MMP-1 are associated 
with poor RFS. IKKα expression was associated 
mainly with ER-positive tumors, whereas IKBKβ, p50, 
and p65 from the canonical, and NIK, p52 and RELB 
from the alternative NF-κB pathway were associated 
with better RFS of breast cancer patients. In 
agreement with our results, Bennett et al. found in 
immunohistochemical (IHC) analysis of a tissue 
microarray of 3626 patients with invasive ductal 
carcinoma of the breast that high cytoplasmic IKKα 
was associated with shorter disease-free survival (also 
named relapse-free survival) and recurrence-free 
survival of patients treated with tamoxifen [58]. When 
they analyzed the patients according to the molecular 
subtype Luminal A, they observed a shorter RFS 
when IKKα was highly expressed in the cytoplasm 
and the nucleus of tumor cells, and that nuclear 
expression was associated with ER-positive tumors 
[58]. In another study, Bennet et al. also demonstrated 
that phosphorylated-p65 was associated with worse 
cancer-specific survival and increased tumor grade 
[25]. Different authors have pointed out that the 
NF-κB pathway is associated with a poor outcome in 
another type of cancers: NF-κB/p65 expression was 
evaluated by IHC in biopsies of 50 patients with rectal 
cancer undergoing neoadjuvant chemo or 
radiotherapy and surgery. The results suggested that 
the high level of NF-κB/p65 is associated with 
shortened OS [59]. In a different study, it was reported 
that p50-/- mice had smaller tumors and displayed 
high levels of IL-12 and CXCL10. Importantly, the 
administration of those cytokines in mice restrained 
colitis-associated cancer. Interestingly, the authors 
observed a high density of NK, NKT and CD8+ T cells 
[60]. Cai et al observed poor survival associated with 
p50 nuclear expression in diffuse large B-cell 
lymphoma. 
On the other hand, we observed that expression 
of IKBKβ, p50, and p65 from the canonical, and NIK, 
p52 and RELB from the alternative NF-κB pathway 
were associated with better RFS of breast cancer 
patients. We were surprised with this finding to set 
the least and we presently do not have an explanation 
for this association. It is possible that mRNA 
expression does not correlate with protein levels or 
function and that what we are observing is a negative 
control loop in which high activity leads to less 
expression. It is also possible that some components of 
the NF-κB pathway have a stronger effect on 
promoting tumor growth than others, and as cancer 
progresses, these less pathogenic components are 
selected against. In agreement with the former 
explanation, Bennet et al observed that in spite of 
lower expression of IKKβ, the knockdown of this 
protein in breast cancer cell lines increased apoptosis 
and reduced cell viability [25]. On the contrary, in 
patients with diffuse large B-cell lymphoma of the 
germinal center subtype and with TP53 mutations, it 
was found that p50 nuclear expression correlated with 
significantly better clinical outcome [61]. This study 
agrees with a potentially better prognosis of some of 
the NF-κB components and with our observation that 
the expression of p50 correlated with better RFS in 
patients with ER-positive and negative breast cancer, 
Luminal A and even in basal tumors. Differences in 
the prognostic value may also be a reflection of the 
dual role of tumor-promoting and anti-tumor effects 
of inflammation [46].  
Other studies support that the alternative 
pathway of NF-κB is associated with poor prognosis 
in solid tumors such as glioblastoma, and in mouse 
models, it has been observed that NF-κB 
up-regulation is associated with a more aggressive 
subtype of this disease [62, 63]. Also, in prostate 
cancer, the nuclear expression of RELB was associated 
with advanced tumors [64, 65]. In breast cancer, the 
patron of NIK expression was analyzed by IHC in the 
tumor and adjacent non-cancerous tissue specimens 
of 82 patients. They observed higher expression in 
cancerous than in adjacent tissues and a significant 
correlation with lymph node metastasis and lower 
five-year survival [66]. Also, patients with higher 
expression of RELB had decreased RFS and OS in 
ER-positive breast carcinoma [67]. Moreover, in other 
tumors such as lung cancer, the expression of NIK and 
RELB was associated with metastasis and shorter OS 
[68, 69]. These studies are contrary to what we have 
observed regarding NIK and RELB mRNA expression.  
The measurement of the expression of 
transcriptional targets of a given signaling pathway 
may provide a more intuitively accessible assessment 
of prognostic values. Several proinflammatory 
cytokines, growth factors, and proteases are regulated 
by both the classical and alternative NF-κB pathway 
[16, 17]. It is worth noticing that the NF-κB targets 
analyzed in this study were associated with a poor 
prognosis suggesting increased activity of the 
pathway [46, 70-72]. We observed an association of 
IL-8 and MMP-1 expression with poor RFS and OS in 
breast cancer patients, regardless of ER or nodal status 
or molecular classification. In the plasma and serum 
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of breast cancer patients, the concentration of IL-8 
correlated with poor recurrence-free survival in 
patients with Her2- tumors and patients with 
metastasis [73, 74]. Using a public database, 
McGowan and Duffy analyzed the expression of 17 
MMPs in the outcome of breast cancer patients. In 
their study, only MMP-1 was highly expressed in 
tumors ˃2 cm in size and MMP-1 and other MMPs 
were associated with poor OS [75]. Wang et al. 
demonstrated that MMP-1 expression was associated 
with poor OS in grade II, nodal-negative, ER-positive 
and Her2-negative breast cancer using the same 
database as us [76].  
Even though in our study the expression of IL-6 
was associated with better survival, its overexpression 
is associated with tumor growth, progression and 
response to therapy in many types of cancer [77-80]. It 
has been observed that in patients high serum levels 
of IL-6 are associated with poor prognosis and shorter 
survival [81-83]. STRING analyses showed that IL-6 is 
connected with STAT3. The activation of the 
IL-6/STAT-3 signaling axis apparently is an 
important event in cancer because it promotes 
carcinogenesis by regulating multiple survival 
signaling pathways in tumor cells [84]. STAT3 is also 
an important regulator of immune cell function, it has 
been linked to cancer [85]. Some studies support an 
NFκB and STAT3 crosstalk required for 
communication between tumor cells and their 
microenvironment (reviewed in [86]). Our STRING 
analysis also shows that IL-4, IL-10 are regulated by 
NFκB. Like IL-6, it has been shown that the expression 
of IL-4 and IL-10 is associated with cancer [87-89]. 
However, it seems that their greatest participation is 
not in the tumor cell itself but in regulating its 
microenvironment. IL-4 and IL-10 together with IL13, 
M-CSF, and CCL2 participate in the polarization of 
monocytes to macrophages, whose function is to favor 
activities such as tissue repair [90]. These 
macrophages in the tumor microenvironment and 
their chemical mediators favor the processes of 
invasion, angiogenesis, lymphangiogenesis, 
intravasation, extravasation, and metastasis [91-93]. 
Among these mediators are CSF-1 (Colony 
Stimulating Factor-1), GM-CSF (Granulocyte- 
macrophage- Colony Stimulating Factor), MSP 
(Macrophage Stimulating Factor), TGF-β, chemokines 
(CCL2, 3, 4, 7 and 8), MMPs, cathepsins (B and D), 
VEGF (Vascular Endothelial Growth Factor), and 
angiopoietin 1 and 2 [91-93]. These studies suggest 
that the activation of the NF-κB pathway not only 
influences the tumor cells but also regulates their 
microenvironment. 
In our study, we do not know to which extent the 
expression of the genes related to the NFκB pathway 
stems from the tumor cells or is influenced by the 
presence of cells in the microenvironment of the 
tumor biopsies. Therefore, we analyzed the 
expression of the gene panel mentioned above in 
different breast cancer cell lines representing the 
luminal, basal and Her2-positive subtypes. 
Interestingly, we found that the expression of those 
genes was different in each cell line, even when they 
are classified in the same molecular subgroup (Figure 
4). This could be explained by the huge heterogeneity 
within the cell lines considering the influence of 1) 
cancer stem cells (CSCs) [94, 95], 2) clonal evolution 
[96], and 3) tumor cell plasticity [97, 98]. Even with 
these results, we could observe that mainly genes 
associated with the alternative NF-κB pathway were 
prominently expressed in cell lines with more 
aggressive characteristics. NIK and RELB were mainly 
expressed by the basal breast cancer cell line 
MDA-MB-231. Consistent with these data, the 
expression of NIK has been associated with the 
proliferation of basal-like subtype of breast cancer [49, 
99]. Vazquez-Santillan et al. described that 
MDA-MB-231 CSCs showed activation of NF-κB 
through NIK and this was essential for the 
maintenance of the stemness phenotype [48]. 
However, in acute myelogenous leukemia (AML), it 
was reported that NIK stabilization acts as a tumor 
suppressor, and this stabilization induced the 
alternative pathway of NF-κB. Interestingly, they 
observed that the expression of RELA (p65) was 
reduced favoring tumor shrinkage. While RELA 
overexpression promoted tumor growth and 
vice-versa, RELB overexpression decreased tumor 
growth [100]. Bennett et al. demonstrated that 
silencing the expression of IKKα only affected the 
proliferation of the Luminal A breast cancer cell line 
MCF-7 and not the Basal cell line MDA-MB-231 [58]. 
In agreement, Park et al. demonstrated that IKKα 
participates in the regulation of estrogen-genes such 
as cyclin D1 and c-myc [101].  
Under basal cell culture conditions, the p65 
subunit was largely present in the cytoplasm of all cell 
lines, and only very few cells of aggressive basal cell 
lines MDA-MB-231 and -468 showed nuclear 
localization of p65, which would explain why IL-8 
and MMP-1 are more highly expressed in the basal 
cell lines. In agreement with that, Espinoza-Sánchez et 
al. showed that p65 is cytoplasmic in the 
non-aggressive cell lines MCF-7 and T47D while it is 
mostly nuclear in the aggressive basal subtype cell 
lines HS578T and MDA-MB-231 [22]. Notably, these 
cells secrete more IL-8 than non-aggressive cells in 
which p65 showed a cytoplasmic localization [22]. 
They also observed that, after the treatment of MCF-7 
and T47D cells with the conditioned media of basal 
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cells, p65 was translocated to the nucleus, 
emphasizing a role for the tumor microenvironment 
and of the lateral transmission of malignant 
properties for NF-κB activation. These 
induced-aggressive cells increased the expression of 
chemokine receptors, CSC markers, invasiveness, and 
exhibited a signaling signature that involved NF-κB 
activation and the participation of IL-8, MCP-1, 
G-CSF, GM-CSF, MMP-1, and -2 [22, 102]. In our 
study, we observed that after the stimulation with 
TNF-α all cells translocated p65 to the nucleus, which 
suggests that NF-κB was activated. Indeed, a previous 
study demonstrated that after the treatment with 
TNF-α around 90% of breast cancer cells lines 
translocated p65 to the nucleus and that this 
activation correlated with the induction of migration 
of non-migratory cells [103]. Conversely, blocking 
NF-κB activation inhibited the invasion capacity of 
the basal cell line MDA-MB-231 [103]. Interestingly, 
immunohistochemical detection of nuclear p65 in 
tumor samples of breast cancer patients was 
associated with reduced disease-free survival (DFS or 
RFS) in the same study [103].  
Conclusion  
In summary, our results suggest that the 
expression of NF-κB related genes influences the 
prognosis of breast cancer patients. Particularly IKKα, 
IL-8, and MMP-1 emerge as important targets for the 
treatment of BC patients, especially IKKα for 
ER-positive tumors Selective novel compounds 
targeting the NF-κB pathway may offer a promising 
therapeutic approach. For example, the FDA (Food 
and Drug Administration) and the European 
Medicines Agency approved the proteasome inhibitor 
Bortezomib for the treatment of multiple myeloma, 
which also affects the NF-κB pathway [104]. Tools like 
KMplot hold a lot of promise for the study of genes in 
specific pathways and relating them to patient' 
survival, pointing out therapeutic targets for more 
specific treatments. Our study illustrates the need to 
design studies of signaling pathways at the gene 
expression and protein levels to understand more 
about their link to prognostic biomarkers and cancer 
classification schemes (TNM, grade or molecular). 
This is a prerequisite for designing personalized 
treatments that could have a significant economic 
impact, as the application of unnecessary 
chemotherapy and its complications such as toxicity, 
heart problems, and infections will be avoided.  
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